Covis Pharma has begun a phase 3 trial of its approved asthma drug Alvesco (ciclesonide) in non-hospitalized COVID-19 patients ages 12 years and older.
The drugmaker will test the inhaled treatment in 400 patients at multiple sites. Participants will receive Alvesco with the standard supportive care or a placebo with standard supportive care.
The primary endpoint will be the percentage of patients who were admitted to the hospital or died by day 30.
Early results of the trial are expected by late August or early September. — Jordan Williams